Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol by Kavallaris, M et al.
Taxol is an important anti-tumour agent that is particularly effec-
tive in the treatment of ovarian and breast carcinomas, although its
usefulness is often hampered by the development of drug resis-
tance. Taxol binds to the b-tubulin subunit of the microtubule (Rao
et al, 1995) of which six distinct b-tubulin isotypes have been
identified in mammalian cells (Lewis and Cowan, 1990; Luduena,
1998). Tubulin forms a heterodimer that consists of a- and b-
tubulin subunits that constitute the microtubule. Microtubules are
an integral part of the cytoskeleton and play a crucial role in
chromosomal separation and segregation (Hyams and Lloyd,
1994). The genes that encode tubulin have been highly conserved
throughout evolution and, even within species, multiple a- and b-
tubulin genes encode distinct tubulin gene products (Sullivan &
Cleveland, 1986).
Taxol resistance has been attributed to a number of mechanisms
including induction of the multidrug resistance phenotype and over-
expression of P-glycoprotein (Horwitz et al, 1993). In addition,
changes in the composition and mutations in b-tubulin isotypes have
been identified in cells resistant to Taxol (Haber et al, 1995;
Jaffrezou et al, 1995; Dumontet et al, 1996; Giannakakou et al,
1997; Kavallaris et al, 1997; Ranganathan et al, 1998a). We recently
reported that expression of specific b-tubulin isotypes increased in
Taxol-resistant epithelial ovarian tumours and that these changes
were similar to those identified in Taxol-resistant human lung cancer
cells, A549-T12 and A549-T24 (9- and 17-fold resistant to Taxol
respectively) (Kavallaris et al, 1997). The Taxol-resistant ovarian
tumours displayed significant increases in two brain-specific b-
tubulin isotypes, Hb4 (class III) and H5b (class IVa), which are not
normally expressed in epithelial tissues.
Microtubule dynamics can be influenced by the composition of
b-tubulin isotypes, and aberrant expression of specific isotypes
could confer a survival advantage to cells when exposed to a drug
such as Taxol. There is evidence that altering the b-tubulin isotype
composition in vitro can modulate microtubule dynamics in
response to Taxol (Derry et al, 1997). Microtubules composed of
class III (Hb4 gene product), or class IV (H5b and Hb2 gene
products) b-tubulin were significantly less sensitive to the effects
of bound Taxol than microtubules assembled from unfractionated
tubulin. This finding strongly suggests that alterations in b-tubulin
isotype composition may play a role in resistance to antimitotic
agents that target the tubulin/microtubule system. While there is
increasing support for the idea that b-tubulin isotype composition
alters microtubule dynamics and response to drugs such as Taxol
in vitro (Banerjee et al, 1990; Lu and Luduena, 1993; Derry et al,
1997), there is limited knowledge concerning its role in Taxol
resistance in cells. Recently, Ranganathan et al (1998b) demon-
strated that in human brain cell lines intrinsically expressing
different levels of class III b-tubulin, those cell lines with the
higher level of this isotype were less sensitive to the effects of
Taxol. To date, there is no direct evidence that altered expression
of the brain-specific class III b-tubulin isotype in Taxol-resistant
cells contributes to the resistance phenotype.
Antisense oligonucleotides have been used successfully to
block the expression of a number of genes so that their function
and cellular interactions could be better elucidated (Helene and
Toulme, 1990). To identify a possible role for an increased expres-
sion of b-tubulin isotype, Hb4, in Taxol resistance, antisense
oligodeoxynucleotides (ODNs) were targeted to various regions of
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the Hb4 gene. The effect of antisense oligonucleotide treatment on
Taxol-resistant A549-T24 cells was characterized at the mRNA
and protein levels. Antisense oligonucleotides successfully
decreased the expression of the class III b-tubulin isotype in
Taxol-resistant non-small-cell lung cancer cells. Decreased
expression of the class III b-tubulin isotype corresponded with an
increased sensitivity to Taxol. This is the first report implicating a
direct relationship between Taxol resistance and altered expression
of a brain-specific isotype in tumour cells of epithelial origin.
MATERIALS AND METHODS
Cell culture and treatment with oligonucleotides
Human non-small-cell lung cancer cells (A549-T24) selected for
resistance to Taxol, were maintained in 24 nM Taxol, RPMI-1640
containing 1% penicillin–streptomycin (Gibco Laboratories,
Grand Island, NY, USA) and 10% fetal bovine serum (FBS)
(Kavallaris et al, 1997). Phosphorothioate ODNs designed to
various regions of the Hb4 gene (Figure 1) were synthesized
at Gene Link (Thornwood, NY, USA) as shown in Table 1. Lipo-
fectin was preincubated in OPTI-MEM (20 mgm l –1 Lipofectin;
Gibco Laboratories, Grand Island, NY, USA) for 40 min at room
temperature prior to the addition of various concentrations (as
specified in the figure legends) of phosphorothioate ODN in
OPTI-MEM for 15 min at room temperature to allow for the
formation of ODN–lipofectin complexes. A549-T24 cells were
plated onto 35-mm dishes in 2 ml RPMI-1640 containing 4 nM
Taxol and 10% FBS at a concentration that achieved approxi-
mately 60% confluency within 24 h. Cells were washed twice with
1 ml OPTI-MEM, followed by the addition of ODN–lipofectin
complexes and further incubated at 37°C for 4 h. Cells were
washed and incubated in fresh RPMI medium at 37°C for 20 h.
After a final round of washing, the cells were treated using the
same procedure with half the concentration of ODN (0.5 mM)
unless otherwise stated. A549-T24 cells were maintained in 4 nM
Taxol throughout the duration of each experiment. This concentra-
tion was chosen so as to avoid increased Taxol toxicity in cells
exhibiting down-regulation of the class III b-tubulin isotype.
Conditions were selected so that there was less than 10% differ-
ence in the number of viable cells in the ODN-treated versus lipo-
fectin only samples, as determined with a vital dye assay. All
experiments included the use of a scrambled ODN and lipofectin
only control.
Cellular accummulation and intracellular distribution of
FITC-labelled oligonucleotide
The accumulation of fluorescein isothiocyanate (FITC)-labelled
(Gibco Laboratories) ODNs in cells was monitored using a fluo-
rescence microscope. FITC-ODN had the same base composition
and length as AS1 ODN. A549-T24 cells were plated on cover-
slips in 35-mm dishes, incubated at 37°C for 24 h and treated once
with 1 mM FITC-labelled ODN prior to monitoring cellular uptake.
Briefly, cells were harvested at 4 and 24 h following ODN treat-
ment, fixed with 70% ethanol–phosphate-buffered saline (PBS)
for 20 min and mounted on glass slides using 70% glycerol in
PBS. Cells were visualized for uptake and intracellular distribu-
tion of FITC-labelled oligonucleotides with a Zeiss Axioskop
microscope fitted with epifluorescence illumination.
Determination of b-tubulin gene expression by RT-PCR
Following ODN treatment of the A549-T24 cells, b-tubulin
analysis was performed as previously described (Kavallaris et al,
1997). Briefly, total cellular RNA was isolated from ODN treated
A549-T24 cells, DNase I treated to remove any contaminating
DNA, and reverse transcribed for reverse transcription polymerase
chain reaction (RT-PCR) analysis. Experiments were performed
twice, with three independent PCR reactions being done for each
sample.
Immunofluorescence and digital scanning
A549-T24 cells were grown on glass coverslips to approximately
60% confluency. The cells were treated as described under ‘Cell
culture and treatment with oligonucleotides’. Briefly, cells were
subjected to two ODN (1 and 0.5 mM respectively) treatments
which were 24 h apart, prior to staining the cells with either mono-
clonal antibody (mAb) to a-tubulin (Sigma; 1:200 dilution, 1%
bovine serum albumin (BSA) in PBS), or mAb to class III b-
tubulin (Sigma; 1:50 dilution, 1% BSA in PBS) and detection with
Table 1 Oligonucleotide sequences
Oligomer Sequencea Target
AS1 ACGTGGGCGACTCGG ORFb
AS2 TCTTCTCACAAGTACGTG ORF
AS3 TTGCTCTGGATGGCC ORF
AS4 GCGCCAAGTGAAACTG ORF and stop codon
SCR 1 CTTACTAGCTTAGTACGA Scrambled ODN
SCR 2 GCCGCAGTCGGAGTG Scrambled ODN
aAll sequence entries written in the 5¢ to 3¢ direction. bORF, open reading
frame.
1 100 200 300 400 450 3´UTR
448–stop codon 332–336 55–60 36–40
AS1 AS2 AS3 AS4
aa
Figure 1 Schematic diagram of Hb4 cDNA sequence. Sequences were selected against Hb4 b-tubulin in regions where the greatest divergence between the
isotypes exist. The location of the antisense sequence is listed by amino acid position and the name of each antisense oligonucleotide is listed below each
indicated sequence (Genbank accession U47634)1022 M Kavallaris et al
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Cy3-conjugated anti-mouse IgG (Amersham 1:1000, 1% BSA
in PBS). Fluorescence was quantitated using an Olympus IX70
inverted microscope and digitizing the images with a Photometrics
PXL camera as previously described (Kavallaris et al, 1997).
Growth inhibition assays
Cells were plated in triplicate at a concentration of 1 ´ 105 cells per
ml (2 ml per well) in 6-well plates and allowed to attach for 24 h
prior to treatment with ODN as described for the immuno-
fluorescence procedure. Following the two ODN treatments (1 and
0.5 mM respectively), A549-T24 cells were exposed to varying
amounts of Taxol (0–20 nM) for 72 h. The half-life of phospho-
rothioate ODNs is in excess of 48 h (Wagner, 1994); therefore, the
cells were treated twice to ensure that optimum down-regulation of
class III b-tubulin was maintained during the cytotoxicity assay.
Cells were trypsinized and counted on a Coulter counter (model
ZF0031; Coulter Electronics Inc., Hialeah, FL, USA). Three
independent experiments using triplicate plates were performed.
RESULTS
Effect of oligonucleotides on Hb4 mRNA levels
Antisense oligodeoxynucleotides (ODN) have been designed for
complimentarity to various regions of the human b-tubulin Hb4
gene (Figure 1 and Table 1). Due to the high nucleotide homology
of the six human b-tubulin isotypes, limited regions were available
on the Hb4 gene to design antisense ODNs with high specificity
and no cross-reactivity. Four ODNs were synthesized as well as a
general scrambled ODN control, SCR 1 (Table 1). In initial experi-
ments, cells were treated with 1 mM ODN for 4 h. No difference in
cell membrane integrity was found between the antisense-treated
and control cells as determined by the trypan blue exclusion dye
over a 72-h period (data not shown). Hb4 gene expression was
determined by competitive RT-PCR (Kavallaris et al, 1997).
Following two treatments with 1 mM ODN, 24 h apart, two of the
antisense ODNs, AS1 and AS3, were found to decrease the expres-
sion of the Hb4 gene by approximately 40–50% (Figure 2). These
results were obtained in two separate experiments, with the PCR
being performed in triplicate for each run. Subsequent experiments
utilized AS1 ODN and its corresponding control, SCR 2 ODN, as
AS1 ODN was able to substantially decrease the Hb4 message
within 24 h from the initial ODN exposure, while AS3 ODN
required two treatments (data not shown).
Uptake and cellular distribution of ODN
To ensure that the antisense ODN effect was due to efficient accu-
mulation of the ODN–lipofectin complex, A549-T24 cells were
examined for their ability to accumulate FITC-AS1 ODN (Figure
3). Following a 4-h treatment with FITC-AS1 ODN, all of the cells
showed substantial cytoplasmic localization in granular compart-
ments and nuclear accumulation. A similar effect was noted when
cells were observed at 24 h. The accumulation of fluorescence in
the cells is likely to represent FITC-ODN, and not disassociated
FITC, due to the stability of phosphorothioate ODNs in culture
(Akhtar and Juliano, 1992; Wagner, 1994).
Concentration-dependent reduction of Hb4 message by
AS1 ODN
Treatment of A549-T24 cells with AS1 ODN resulted in a concen-
tration-dependent inhibition of Hb4 message (Figure 4). Reduction
of Hb4 message levels was observed at concentrations of 0.1 mM
AS1 ODN. At 1 mM, maximum specific effects were observed
following treatment, which resulted in a 46% decrease in message
compared to 1 mM of the matched scrambled control, SCR 2 ODN.
No concentration-dependent specific effect on Hb4 message levels
was observed with the SCR 2 ODN and there was no significant
difference between the SCR 2 ODN and the lipofectin only control
(Figure 4). Higher levels of AS1 were tested but resulted in unac-
ceptable levels of toxicity (> 10% cell death; data not shown). Gene
expression of the constitutively expressed b-tubulin isotype HM40
(class I) in the A549-T24 cells was unaltered following AS1 treat-
ment compared to SCR 2 and lipofectin only control (Figure 5).
Expression levels of the b-tubulin isotype Hb9 (class II) gene in the
A549-T24 cells were unchanged between AS1 and SCR 2,
although these levels were slightly higher than those observed in
the lipofectin only control (Figure 5). The levels of the other three
b-tubulin isotypes, H5b, Hb2 and Hb1, were not altered following
AS1 treatment (data not shown). In contrast, there was a decreased
expression of the class III b-tubulin isotype, Hb4, compared to
either the SCR 2 or lipofectin only control.
Inhibition of class III b-tubulin protein
To establish whether a decrease in Hb4 gene product corresponded
to a decrease in the class III b-tubulin protein, antisense-treated
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Figure 2 Effect of antisense oligonucleotides on Hb4 b-tubulin expression.
A549-T24 cells were treated with 1 mM ODN as described in Materials and
Methods. RNA was isolated 24 h after the second ODN treatment and
reverse transcribed. Competitive RT-PCR analysis of Hb4 b-tubulin gene
expression using b2-microglobulin as an internal standard was performed.
(A) Representative gel of the Hb4 b-tubulin and b2-microglobulin PCR
products from A549-T24 cells following treatment with ODNs. RT-PCR
products were separated on 10% PAGE followed by ethidium bromide
staining. Lane C, lipofectin only control; Lane W, water control. (B) Ratios
between the Hb4 PCR product and the b2-microglobulin PCR product were
determined and results were expressed as a percentage of the mean value
of the lipofectin only control. The experiment was done twice and the results
represent three independent RT-PCR reactions for each experimentAntisense oligonucleotides modulate Taxol resistance 1023
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A549-T24 cells were stained with mAb to either a-tubulin or class
III b-tubulin and visualized with a fluorescent secondary antibody.
Immunostained cells were imaged with a digital camera
attached to a fluorescence microscope and the mean fluorescence
intensity of at least 100 individual cells was measured after AS1
ODN, SCR 2 ODN or lipofectin only treatments (Figure 6). This
technique has previously been used to measure tubulin levels in
cells (Kavallaris et al, 1997). A clear decrease in class III b-tubulin
immunofluorescence intensity was observed in the antisense-
treated cells compared to both the SCR 2 and lipofectin only
controls. In contrast, the fluorescence intensity of total a-tubulin
expression in AS1-treated cells gave a similar frequency distribu-
tion to SCR 2 and lipofectin only control.
Effect of antisense ODN on Taxol sensitivity
After establishing that AS1 ODN could decrease Hb4 expression at
both the message and protein levels, 72 h cytotoxicity assays were
performed on treated cells to determine whether this decrease
resulted in modulation of Taxol resistance in A549-T24 cells.
Cytotoxicity assays demonstrated a significant increase of 39.3% in
Taxol sensitivity in the A549-T24 cells treated with AS1 compared
4 h 24 h
A B
Figure 3 Incorporation and distribution of FITC-AS ODN in A549-T24 cells. Cells were treated with 1 mM FITC-AS1 and examined at 4 (A) and 24 h (B) after
initial treatment as described in Methods. Cells were imaged on a fluorescence microscope using a 60´ oil immersion objective
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Figure 4 Dose–response for oligonucleotide inhibition of Hb4 message.
A549-T24 cells were treated with 0.02–1 mM AS1 (solid bar) or SCR 2 (white
bar) for 4 h and expression analysis was performed as described for Figure
2. C, Lipofectin only control (grey bar)
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Figure 5 RT-PCR determination of b-tubulin isotypes following AS
treatment. A549-T24 cells were treated with 1 mM AS1 or SCR 2 (matched
scrambled ODN) for 4 h and expression analysis was performed as
described for Figure 2. Competitive RT-PCR, involving coamplification of
either HM40, Hb9 or Hb4, and control b2-microglobulin gene sequences,
were subjected to 35 cycles and the products were separated on 10% PAGE
followed by ethidium bromide staining. Lane W, water control1024 M Kavallaris et al
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to the A549-T24 cells treated with the scrambled ODN (P < 0.005)
(Table 2). A lipofectin only control was included in each experi-
ment and a significant increase in Taxol sensitivity was also
observed in the AS1 ODN-treated cells compared to this control
(P < 0.05). Three independent experiments were performed.
DISCUSSION
Taxol is an effective chemotherapeutic agent whose usefulness is
often negated by the development of drug resistance. There has
been increasing support in the literature that altered expression of
specific b-tubulin isotypes, in response to the development of
resistance to antimitotic drugs such as Taxol, may be involved in
this phenotype (Haber et al, 1995; Jaffrezou et al, 1995; Derry et
al, 1997; Kavallaris et al, 1997; Ranganathan et al, 1996, 1998a,
1998b). Our laboratory recently has described increased expres-
sion of two brain-specific b-tubulin isotypes, Hb4 (class III) and
H5b (class IVa), in response to Taxol resistance in both human
epithelial ovarian carcinoma and human lung cancer cell lines
(Kavallaris et al, 1997). Antisense ODNs were selected against the
Hb4 b-tubulin gene since the expression level of this isotype was
barely detectable in the parental A549 cells and it was the second
most abundant isotype in the Taxol-resistant A549-T24 cells, after
the constitutively expressed HM40 (class I) isotype. We describe
here, for the first time, that inhibition of expression by antisense
ODN of the class III b-tubulin isotype sensitizes Taxol-resistant
cells to Taxol, strongly suggesting that tubulin isotypes are likely
to be important in the development of resistance to Taxol.
Phosphorothioate antisense oligonucleotides were selected for
this study due to their resistance to degradation by cellular
nucleases and their relatively long half-life in culture (Helene and
Toulme, 1990; Wagner, 1994). Furthermore, antisense ODNs have
previously been used to inhibit the expression of proteins associ-
ated with drug resistance (Alahari et al, 1996; Stewart et al, 1996).
We demonstrated that two ODNs, AS1 and AS3, could decrease
Hb4 mRNA levels by 40–50%. While antisense ODNs are a valu-
able tool for the study of gene function, it is important to ensure
that the observed effects are specific for the desired gene and that
appropriate controls are included (Helene and Toulme, 1990;
Wagner, 1994).
Since ODNs in some instances can be degraded in culture and
cause non-specific effects (Wagner, 1994), a matched scrambled
ODN, SCR 2, was utilized in our study which had the same length
and a similar base composition as that of the AS1 ODN. Down-
regulation of the expression of the class III b-tubulin gene, Hb4,
was specific to this isotype as no change was observed in the levels
of the constitutively expressed HM40 gene, or any of the other
b-tubulin isotypes. Following AS1 ODN treatment, a significant
decrease in the staining intensity of the class III b-tubulin protein
was observed. This effect was specific to the class III protein, as no
change in the total a-tubulin staining was visible. Total a-tubulin
levels are often coordinately regulated with total b-tubulin levels
(Gonzalez-Garay and Cabral, 1995). Since the total a-tubulin
levels were similar between the AS1 treatment and the two
controls, the down-regulation of the class III b-tubulin did not
appear to affect the total tubulin levels. Of significance is the
observation that the decreased expression of the class III b-tubulin
protein in the A549-T24 cells resulted in an increase in sensitivity
to Taxol. Our study clearly demonstrates that AS1 ODN specifi-
cally targets the Hb4 message and that this results in decreased
levels of the class III protein with a concomitant increase in Taxol
sensitivity.
Microtubules are dynamic structures that are in a state of
dynamic instability, that is, continuously growing and shortening
(Mitchison and Kirschner, 1984). These important cytoskeletal
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Figure 6 Distribution of fluorescence intensity as a measurement for tubulin expression in A549 cells treated with antisense oligonucleotides. A549-T24 cells
were treated twice with either AS1, SCR 2 (1 and 0.5 mM), or lipofectin only control for 4 h, with an interval of 24 h between initial exposures. Cells were probed
with mAb to either total a-tubulin (A) or class III b-tubulin (B) 24 h after the second treatment. The average pixel intensity was determined for a minimum of 100
stained cells. Intensity distribution was determined for each treatment. Treatments were as follows: black bars, AS1; grey bars, SCR 2; and white bars, lipofectin
only control. This experiment was done three times with similar results being obtained each time. This immunofluorescence data is a representative experiment
Table 2 Effect of b-tubulin Hb4 antisense ODN treatment on Taxol
sensitivity in A549-T24 cells
ODN treatment ID50
a (nM Taxol) Increase in Taxol sensitivity (%)b
AS1 46.6 ± 3.3 39.3c
SCR2 76.7 ± 5.5 –
Control 61.2 ± 5.3 –
aID50, drug concentration that inhibits cell division by 50% after 72 h.
bDetermined by calculating the % change between AS1 and SCR2.
cP < 0.005.Antisense oligonucleotides modulate Taxol resistance 1025
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proteins are critical for cell growth and division, and are the target
of a number of important chemotherapeutic agents (Jordan and
Wilson, 1998). It has been demonstrated that microtubule dynamics
in vitro are influenced by the b-tubulin isotype composition (Panda
et al, 1994). In addition, microtubules depleted of class III b-
tubulin polymerize more readily in the presence of Taxol than
microtubules that are not depleted (Lu and Luduena, 1993). These
data suggest that cells expressing higher levels of the class III b-
tubulin isotype may be less sensitive to the effects of Taxol than
cells expressing lower levels of this isotype. Recently, Derry et al
(1997), using purified b-tubulin isotypes, demonstrated that micro-
tubules composed of the class III or class IV b-tubulin isotype were
approximately sevenfold less sensitive to the effects of Taxol than
microtubules assembled from unfractionated tubulin. This study
strongly indicated that b-tubulin isotype composition influences the
sensitivity of microtubule dynamics to bound Taxol. Consistent
with this proposal, decreasing the levels of class III b-tubulin in
Taxol-resistant cells increased their sensitivity to Taxol.
We have previously suggested that expression of specific b-
tubulin isotypes could alter microtubule dynamics in a way that could
reduce the effectiveness of Taxol (Kavallaris et al, 1997). In support
of this, a recent study found a positive correlation between increasing
resistance to Taxol and increasing expression of the class III b-
tubulin isotype among Taxol-resistant human prostate carcinoma
cells (Ranganathan et al, 1998a). These data are consistent with
our findings in Taxol-resistant human lung cancer cells in which
increased levels of the class III b-tubulin isotype corresponded to an
increase in Taxol resistance (Kavallaris et al, 1997). Furthermore,
two human brain carcinoma cell lines which intrinsically expressed
high levels of the class III b-tubulin isotype were significantly more
resistant to Taxol than one which had no detectable levels as deter-
mined by immunoblot analysis (Ranganathan et al, 1998b). All three
brain carcinoma cell lines accumulated equal amounts of Taxol,
eliminating decreased accumulation of drug as a possible mechanism
for decreased sensitivity to Taxol.
Tubulin is the target of a number of chemotherapeutic agents
and a broader understanding of the interaction of these drugs in the
tubulin/microtubule system could lead to improved drug targeting.
Our study provides the first direct evidence that class III b-tubulin
isotype levels in a cell can modulate response to Taxol. This study
also raises the potential for therapeutic use of antisense oligo-
nucleotides to specific b-tubulin isotypes to modulate tumour
response to Taxol and other drugs.
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